Physician profile
Nitin Bhatnagar
NPI 1770512485
$14,779.65
in general payments reported to CMS, 2019-2025
33 companies · $2,222 in 2025
The $2,222 reported for 2025 was more than what 85% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,618 · 2020: $1,687 · 2021: $2,523 · 2022: $2,215 · 2023: $2,308 · 2024: $2,207 · 2025: $2,222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,737.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,737.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,191.22 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,733.26 | 2019-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $1,459.74 | 2019-2025 | Farxiga, Lokelma, Wainua |
| Janssen Pharmaceuticals, INC | $1,435.45 | 2019-2024 | Xarelto |
| Amgen INC. | $1,423.87 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $957.71 | 2019-2025 | Jardiance |
| Pfizer INC. | $762.10 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $634.93 | 2021-2025 | Verquvo |
| Kiniksa Pharmaceuticals International, Plc | $487.21 | 2024 | Arcalyst |
| Abbott Laboratories | $457.96 | 2019-2025 | Cardiomems, Mitraclip |
| Esperion Therapeutics, INC. | $426.64 | 2020-2025 | Nexletol |
| Alnylam Pharmaceuticals INC. | $424.69 | 2021-2025 | Onpattro, Amvuttra |
| Amarin Pharma, INC. | $354.12 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $308.81 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $298.40 | 2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $281.91 | 2023-2025 | |
| Kiniksa Pharmaceuticals, LTD. | $200.16 | 2021-2023 | Arcalyst |
| Novo Nordisk INC | $169.70 | 2022-2025 | Wegovy |
| Lexicon Pharmaceuticals, INC. | $129.74 | 2023-2024 | Inpefa |
| Biotronik INC. | $114.18 | 2019-2021 | |
| Heartflow, INC. | $111.80 | 2022-2023 | Ffrct |
| Bridgebio Pharma, INC. | $94.03 | 2025 | Attruby |
| Actelion Pharmaceuticals US, INC. | $52.98 | 2024 | Opsumit |
| Impulse Dynamics (USA) INC. | $42.96 | 2023 | Optimizer |
| Lundbeck LLC | $39.65 | 2019 | |
| Abiomed | $37.43 | 2025 | |
| Tactile Systems Technology INC | $31.16 | 2024 | Flexitouch Plus, Entre Plus |
| Boston Scientific Corporation | $27.41 | 2019 | |
| Altathera Pharmaceuticals LLC | $26.94 | 2024-2025 | Sotalol Hydrochloride |
| Edwards Lifesciences Corporation | $22.17 | 2024 | |
| Venclose INC. | $16.31 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $13.86 | 2019 | |
| Infobionic, INC | $11.15 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nitin Bhatnagar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.